ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.46975
-0.01%
Brent Oil
82.215
0.11%
Bitcoin
66,143.87
-0.74%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) Noticias

MRUS

Merus NV (MRUS)

Merus NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MRUS
FechaHoraFuenteTítuloSímboloCompañía
12/06/202416:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
03/06/202413:30GlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
02/06/202411:30GlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
30/05/202416:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
29/05/202420:30GlobeNewswire Inc.Merus Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:MRUSMerus NV
29/05/202407:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:MRUSMerus NV
28/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
28/05/202415:01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
28/05/202406:00GlobeNewswire Inc.Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCNASDAQ:MRUSMerus NV
23/05/202416:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
13/05/202407:00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
10/05/202415:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
09/05/202415:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
08/05/202415:15GlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
06/05/202415:05GlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
08/04/202411:00GlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
03/04/202407:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
06/03/202407:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:MRUSMerus NV
05/03/202415:30GlobeNewswire Inc.Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionNASDAQ:MRUSMerus NV
04/03/202407:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma ConferenceNASDAQ:MRUSMerus NV
28/02/202415:55Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:MRUSMerus NV
28/02/202415:15GlobeNewswire Inc.Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
14/02/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRUSMerus NV
31/01/202407:00GlobeNewswire Inc.Merus to Participate in Upcoming Investor ConferencesNASDAQ:MRUSMerus NV
15/12/202318:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
02/12/202319:40GlobeNewswire Inc.Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
26/11/202310:05GlobeNewswire Inc.Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
02/11/202315:12GlobeNewswire Inc.Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
23/10/202306:30GlobeNewswire Inc.Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerNASDAQ:MRUSMerus NV
 Showing the most relevant articles for your search:NASDAQ:MRUS

Su Consulta Reciente

EU
ETANF
Republic of France O A T...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados